Renal Transplant

Nephrology
8
Pipeline Programs
3
Companies
3
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 3 programs with unclassified modality

On Market (4)

Approved therapies currently available

Novartis
AFINITORApproved
everolimus
Novartis
Kinase Inhibitor [EPC]oral2009
Novartis
AFINITOR DISPERZApproved
everolimus
Novartis
Kinase Inhibitor [EPC]oral2012
U
EVEROLIMUSApproved
everolimus
Unknown Company
oral2025
Novartis
ZORTRESSApproved
everolimus
Novartis
Kinase Inhibitor [EPC]oral2010

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
2 programs
1
1
EverolimusPhase 41 trial
Anti R-IL2 + CyclosporinePhase 3
Active Trials
NCT01169701Completed71Est. Mar 2014
Veloxis Pharmaceuticals
1 program
1
Change from Prograf to Envarsus XRPhase 41 trial
Active Trials
NCT04838288Active Not RecruitingEst. Jan 2026
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
RituximabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT04033276CompletedEst. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Veloxis PharmaceuticalsChange from Prograf to Envarsus XR
GC BiopharmaRituximab
NovartisEverolimus

Clinical Trials (3)

Total enrollment: 71 patients across 3 trials

NCT04838288Veloxis PharmaceuticalsChange from Prograf to Envarsus XR

Cognitive Outcomes in Stable Renal Transplant Patients Switched FromTacrolimus to Envarsus XR™

Start: Jun 2021Est. completion: Jan 2026
Phase 4Active Not Recruiting

IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies

Start: Jan 2019Est. completion: May 2022
Phase 4Completed

24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients

Start: Aug 2010Est. completion: Mar 201471 patients
Phase 4Completed

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space